端锚聚合酶选择性抑制剂STP1002在胃肠道无靶向毒性且具临床前抗肿瘤疗效
在APC突变结直肠癌模型中,新型口服端锚聚合酶选择性抑制剂STP1002通过稳定AXINs拮抗Wnt/β-catenin通路,在APC突变细胞系及动物模型中显示剂量依赖性抗肿瘤活性,且与G007-LK相比未出现胃肠道靶向毒性。
要点
- STP1002选择性抑制端锚聚合酶1/2,不抑制PARP1/2。
- STP1002在APC突变结直肠癌模型中显示剂量依赖性抗肿瘤活性。
- 与G007-LK相比,STP1002在胃肠道未显示显著靶向毒性。
核心结论
- STP1002是一种新型口服端锚聚合酶抑制剂,在临床前模型中显示抗肿瘤疗效且无胃肠道靶向毒性。
- 数据为STP1002作为潜在端锚聚合酶靶向药物用于APC突变结直肠癌患者的临床试验提供了依据。
研究设计与样本
- 采用体外和体内功能研究对STP1002进行开发和表征。
- 在体内评估STP1002的药代动力学、抗肿瘤疗效和毒性。
主要发现
- STP1002强效、选择性地抑制端锚聚合酶1/2,但不抑制PARP1/2。
- STP1002通过稳定AXINs和拮抗Wnt/β-catenin通路,在部分APC突变结直肠癌细胞系中发挥抗肿瘤活性,但在耐药细胞和APC野生型结直肠癌细胞系中无此活性。
- STP1002口服每日一次给药显示良好的药代动力学特征。
- STP1002以剂量依赖性方式抑制APC突变结直肠癌异种移植动物模型的肿瘤生长,但不抑制APC野生型模型。
- STP1002的抗肿瘤疗效在APC突变结直肠癌患者来源肿瘤异种移植模型中得到确认。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tankyrase inhibition stabilises AXINs and antagonises the Wnt/β-catenin pathway in adenomatous polyposis coli (APC)-mutated colorectal cancer (CRC), suggesting that tankyrase is a potential therapeutic target for APC-mutated CRC. However, clinical trials on reported tankyrase inhibitors have been severely limited by on-target toxicity in the gastrointestinal (GI) tract. Herein, we report a new tankyrase-selective inhibitor, STP1002, having preclinical antitumour efficacy without on-target toxicity in APC-mutated CRC models. METHODS: STP1002 was developed and characterised using in vitro and in vivo functional studies; its pharmacokinetics, antitumour efficacy and toxicity were evaluated in vivo. RESULTS: STP1002 showed potent, selective inhibition of tankyrase 1/2 but not of members of the poly (ADP-ribose) polymerase 1/2 (PARP1/2). STP1002 exerted antitumour activity by stabilising AXINs and antagonising the Wnt/β-catenin pathway in a subset of APC-mutated CRC cell lines but not in inhibitor-resistant cells and APC-wild-type CRC cell lines. STP1002 showed favourable pharmacokinetic profiles for oral administration once daily. STP1002 inhibited tumour growth of APC-mutated CRC xenograft animal models but not of APC-wild type models in a dose-dependent manner. The antitumour efficacy of STP1002 was confirmed using APC-mutated CRC patient-derived tumour xenograft models. STP1002 showed no significant on-target toxicity in the GI tract compared to G007-LK, which shows severe ileum toxicity in preclinical animal models. CONCLUSIONS: These results demonstrate that STP1002, a novel, orally active tankyrase inhibitor, shows preclinical antitumour efficacy without on-target toxicity in the GI tract. Our data provide a rationale for a clinical trial on STP1002 as a potential tankyrase-targeted drug in patients with APC-mutated CRC.
引用
- Kim DY, Kwon YJ, Seo WY, et al. Tankyrase-selective inhibitor STP1002 shows preclinical antitumour efficacy without on-target toxicity in the gastrointestinal tract. Eur J Cancer. 2022. PMID: 35849876. doi:10.1016/j.ejca.2022.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。